Monte Rosa Therapeutics Inc. (GLUE) carries a Roarable Rating of E (Strong Sell) with 25/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $10.63 (-1.21% 1D, market cap $906.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GLUE ranks #922 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GLUE carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $895.1M) and ODTX (Odyssey Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $938.6M). Among the 5-stock peer group, GLUE leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).
Per GLUE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826457), Monte Rosa Therapeutics Inc. generated $151.8M in revenue (-33.2% YoY), -$38.6M in net income, and -$27.5M in free cash flow against $448.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 43.2 (NEUTRAL RANGE)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While GLUE currently carries a cautious 25/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.87) and Max Pain ($11.16) forces dealer call-delta covering toward $27.06.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Monte Rosa Therapeutics Inc. (GLUE) slipped -1.21% to $10.63, trading at 6% of its 52-week range ($9.68 – $25.77). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Singapore report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has initiated a second
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement with Monte RosaMonte
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -33.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GLUE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GLUE. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Monte Rosa Therapeutics Inc. (GLUE) ranks #922 by composite RQD confidence (25/100, grade E) and #364 by equity capitalization ($906.9M). Within this direct 5-issuer industry benchmark cohort, GLUE leads on earnings valuation at N/A trailing P/E, while GLUE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with GLUE at 25/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GLUE
ACTIVE
Monte Rosa Therapeutics Inc. | E | 25/100 | — | — | -35.0% | -1.21% | $906.9M | Benchmark Subject |
| MGTX MeiraGTx Holdings plc | E | 20/100 | — | — | -35.0% | -1.79% | $895.1M | /mgtx-vs-glue → |
| ODTX Odyssey Therapeutics Inc. | D | 46/100 | — | — | — | -0.05% | $938.6M | /odtx-vs-glue → |
| CGEM Cullinan Therapeutics Inc. | E | 32/100 | — | — | -35.0% | -0.66% | $960.8M | /cgem-vs-glue → |
| PRME Prime Medicine Inc. | E | 30/100 | — | — | -35.0% | -5.93% | $805.3M | /prme-vs-glue → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Monte Rosa Therapeutics Inc. (GLUE) reported GAAP revenue of $151.8M (-33.2% vs. FY2024 revenue of $227.1M , and -62.2% cumulative change since FY2023) , GAAP net income of -$38.6M, operating cash flow of -$22.8M, and free cash flow of -$27.5M (-172.3% YoY). On the balance sheet, GLUE closed FY2025 with $448.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $151.8M | -$38.6M | -$22.8M | -$27.5M | $448.7M | — |
| FY2024 (FY) | 2024-12-31 | $227.1M | -$72.7M | $42.0M | $38.0M | $438.7M | — |
| FY2023 (FY) | 2023-12-31 | $401.3M | -$135.4M | -$43.8M | -$43.8M | — | — |
As of 2026-11-03, Monte Rosa Therapeutics Inc. (NASDAQ: GLUE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 25/100 at a spot price of $10.63 (-1.21% 1D, market cap $906.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, GLUE ranks #922 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), GLUE carries a Roarable E (25/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MGTX (MeiraGTx Holdings plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $895.1M) and ODTX (Odyssey Therapeutics Inc.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $938.6M). Among the 5-stock peer group, GLUE leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).
Per GLUE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001826457), Monte Rosa Therapeutics Inc. generated $151.8M in revenue (-33.2% YoY), -$38.6M in net income, and -$27.5M in free cash flow against $448.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
GLUE last traded at $10.63 (-1.21% on volume of 1,767,030 shares), positioning the stock -10.45% below its 50-day simple moving average ($11.87) and -38.13% below its 200-day simple moving average ($17.18). Across its 52-week range of $9.68 to $25.77, GLUE sits at the 5.9% percentile with a 14-day RSI of 43.2 (NEUTRAL RANGE) and an implied next-earnings move of ±9.9% ($9.58 to $11.68).
Monte Rosa Therapeutics Inc. (GLUE) earns a live Roarable RQD composite score of 25/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $10.63 (-1.21% 1D, market capitalization $906.9M).
Monte Rosa Therapeutics Inc. (GLUE) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile lists a market capitalization of $0.9B. Reported revenue is — across FY 2023, FY 2024, and FY 2025, which indicates the company has not reported revenue in the listed periods.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Monte Rosa Therapeutics Inc. (GLUE) reported $151.8M in annual revenue (up from $227.1M in FY2024, -33.2% YoY) and -$38.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($401.3M revenue, -$135.4M net income) through FY2025, GLUE scaled operating cash flow to -$22.8M and free cash flow to -$27.5M, backed by $448.7M in total assets against $0 in total debt.
The only sector-level context available is the Health Care classification and the Biological Products industry label. Beta of 1.0 is reported in the market data, which the RQD Macro Regime pillar references as sector sensitivity, but no specific sector correlations are provided.
Real-time company headlines, analyst actions, and sector developments for Monte Rosa Therapeutics Inc. (GLUE) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Singapore report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
MarketBeat report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
www.marketscreener.com report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Monte Rosa Therapeutics Inc. (GLUE) market action, institutional positioning, and fundamental catalysts.
Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritis Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte
Picked up a starter position in GLUE in my $100K Virtual Cash book at $10.76. Market cap of $927.4M and a 52-week range that has reached $25.77 show the market has previously assigned substantially higher value to the company.. Trading inside a $9.68–$25.77 52-week range with -2.97% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.
@DeltaGamma_99 Agree on the RQD 25/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.76 and keeping dry powder in case we test $10.01.
Negative ROIC of -35%, negative FCF yield of -2.97%, and a 3 of 9 Piotroski F-Score point to weak fundamentals with no reported revenue.. Look at the math on GLUE: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Biological Products (No Diagnostic Substances) demand softens. I'd wait for a retest of $9.47 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: